Home・Akcijų sąrašas・Organon & Co

Organon & Co

Uždarymo kaina

SektoriusSveikatos priežiūra

13.77

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.77

Max

13.77

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-292M -146M
Pardavimai	98M 1.6B
P/E Sektoriaus vid.	17.641 56.659
Pelnas, tenkantis vienai akcijai	0.8
Dividendų pajamingumas	0.58
Pelno marža	-9.355
Darbuotojai	10,000
EBITDA	-38M 371M

Dividendai
By Acuity
Dividendų pajamingumas Sektoriaus vid.	0.58% 2.18%
Kitas uždarbis	2026-11-09
Kitas dividendų mokėjimo data	2026-09-10
Kita Ex Dividend data	2026-11-19

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	63M 3.6B
Ankstesnė atidarymo kaina	13.77
Ankstesnė uždarymo kaina	13.77

Naujienos nuotaikos

By Acuity

75%

25%

306 / 339 reitingas Healthcare

Organon & Co Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-02 20:08; UTC

Organon & Co. shares are trading roughly flat, showing little change since Tuesday's close, amid stability near the upper end of their one-month range.

2026-09-01 23:01; UTC

Organon & Co. shares are lower in after-market trading, continuing a downward trend amid broader market unease over economic data indicating a growth slowdown.

2026-08-28 19:26; UTC

Organon & Co. shares are trading roughly flat, with no specific news identified. The stock remains near the upper end of its one-month trading range.

2026-08-27 23:01; UTC

Shares of Organon & Co. traded lower in after-market hours, continuing a decline observed earlier in the session without any specific company news identified.

2026-08-25 19:36; UTC

Organon & Co. shares are near unchanged, trading within a narrow range with no specific news identified during Tuesday's session.

2026-08-24 23:02; UTC

Organon & Co shares are trading lower in after-market hours. Broader geopolitical tensions, particularly the U.S.-Iran situation, may be influencing market sentiment.

2026-08-21 23:41; UTC

Organon & Co. shares are lower in after-hours trading, following a decline from earlier highs and reaching a session low. No specific news was identified.

2026-08-20 22:01; UTC

Organon & Co shares are trading lower in after-market hours, continuing a downward trend since Thursday's close without any specific news to explain the movement.

2026-08-19 23:01; UTC

Organon & Co shares declined in after-hours trading, reflecting unusual weakness since Wednesday's close. The stock is near the lower end of its one-month range.

2026-08-18 23:51; UTC

Organon & Co shares are higher in after-market trading, reaching a maximum cumulative return shortly after Tuesday's close. No specific news was identified.

2026-08-14 19:26; UTC

Organon & Co. shares are trading roughly flat, remaining above their 20-day moving average and near the upper end of their one-month range.

2026-08-13 23:11; UTC

Organon & Co. shares are trading lower in after-market hours, despite an initial uptick, and remain near the upper end of their one-month trading range.

2026-08-07 20:06; UTC

Shares of Organon & Co. are higher today, continuing a trend since Thursday's close amid a broader market increase. No specific company news was identified.

2026-08-06 23:11; UTC

Shares of Organon & Co. are trading lower in after-market hours, reflecting routine action within its one-month trading range. No specific news was identified.

Akcijų palyginimas

Kainos pokytis

Organon & Co Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Organon & Co akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

306 / 339 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.